File downloaded on 2026-11-04
Source URL: https://medicines.health.europa.eu/veterinary/en/600000049432

Cylanic 250 mg + 62.5 mg tablets for dogs and cats

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:
Cylanic 250 mg + 62.5 mg tablets for dogs and cats

Active substance:
Amoxicillin trihydrate
Potassium clavulanate

Target species:
Dog
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Amoxicillin trihydrate
287.01 milligram(s) / 1.00 Tablet

Potassium clavulanate
74.45 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01CR02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Available in:
Greece

Package description:
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 10 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 30 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 50 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 100 tablets.
oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each.Package sizes:Cardboard box of 250 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Industrial Veterinaria S.A.

Marketing authorisation date:
26/07/2021

Manufacturing sites for batch release:
aniMedica GmbH
aniMedica Herstellungs GmbH
Industrial Veterinaria S.A.
Lelypharma B.V.

Responsible authority:
National Organization For Medicines

Authorisation number:
72290/27/07/2021/K-0244702

Date of authorisation status change:
26/07/2021

Reference member state:
Ireland

Procedure number:
IE/V/0582/002

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Estonia Germany Greece Hungary Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

ie-puar-mr-iev0582002-cylanic-250-mg--625-mg-tablets-for-dogs-and-cats-en.pdf